Compare MPV & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | FENC |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 276.3M |
| IPO Year | N/A | 2001 |
| Metric | MPV | FENC |
|---|---|---|
| Price | $16.31 | $7.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 25.2K | ★ 184.5K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.97 |
| P/E Ratio | $9.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.18 | $4.68 |
| 52 Week High | $16.42 | $9.92 |
| Indicator | MPV | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 29.44 | 47.61 |
| Support Level | $15.65 | $7.51 |
| Resistance Level | $19.08 | $8.16 |
| Average True Range (ATR) | 0.68 | 0.33 |
| MACD | -0.31 | 0.03 |
| Stochastic Oscillator | 22.01 | 36.24 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.